Pediatric fever of uncertain source: Difference between revisions

(I like Tintinalli should go first and then Harbor to reflect that WikEM is for a global EM audience, not specifically for Harbor)
Line 1: Line 1:
== From Tintinalli ==
'''Management of patients who are well-appearing, vaccinated, and no clinical source of fever'''
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
|-
| Age Group
| Evaluation
| Treatment
|-
|
0-28d, ≥38C
SBI incidence of ill appearing: 13%–21%
if not ill appearing: <5%
|
CBC, blood Cx
UA, Ucx
CSF cell count, GS, Cx
CXR (only if resp sx)
Stool testing (if diarrhea present)
|
Admit
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg)
|-
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
<br>SBI incidence of ill appearing: 13%–21%
if not ill appearing: &lt;5%
<br>
| Same as for neonates
|
Discharge if:
1. WBC &lt;15K but &gt;5K and &lt;20% bands
2. UA negative
Admit and perform LP if above are not met
Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis)
|-
|
57d-6mo, ≥38
Non-UTI SBI incidence is estimated to be negligible
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span>&nbsp;
<br>
|
UA and Ucx alone
OR
treat 57-90d using Philadelphia Protocol
|
Discharge if negative
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient
Admit and tx with CTX if fail criteria for d/c
|-
|
57d-6mo, ≥39 (102.2)
SBI incidence is estimated &lt;1%;
non-UTI SBI incidence is estimated to be negligible.
UTI is 3%–8%
|
UA and Ucx alone
OR
UA and Ucx + CBC + blood cx
|
:
Discharge if negative
Treat for UTI as above
If WBC&gt;15K&nbsp;consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr
If WBC&gt;20K&nbsp;consider CXR and CSF
|-
|
&nbsp;6–36 mo
Non-UTI SBI incidence is &lt;0.4%&nbsp;
UTI in girls ≤8%
UTI in boys (&lt;12 mo) ≤ 2%
Uncircumcised boys (1–2 y) remains 2%
|
UA and Ucx in:
(girls 6-24mo)
(circ 6-12mo)
(uncirc 6-24mo)
|
Discharge if negative
Treat for UTI as above as outpatient
|-
| &gt;36mo
| No further w/u is routinely necessary
| <br>
|}
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
== Harbor-UCLA Protocol  ==
== Harbor-UCLA Protocol  ==
===Background===
===Background===
Line 225: Line 366:
#Ceftriaxone
#Ceftriaxone
#LP depending on clinical
#LP depending on clinical
== From Tintinalli ==
'''Management of patients who are well-appearing, vaccinated, and no clinical source of fever'''
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1"
|-
| Age Group
| Evaluation
| Treatment
|-
|
0-28d, ≥38C
SBI incidence of ill appearing: 13%–21%
if not ill appearing: &lt;5%
|
CBC, blood Cx
UA, Ucx
CSF cell count, GS, Cx
CXR (only if resp sx)
Stool testing (if diarrhea present)
|
Admit
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg)
|-
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
<br>SBI incidence of ill appearing: 13%–21%
if not ill appearing: &lt;5%
<br>
| Same as for neonates
|
Discharge if:
1. WBC &lt;15K but &gt;5K and &lt;20% bands
2. UA negative
Admit and perform LP if above are not met
Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis)
|-
|
57d-6mo, ≥38
Non-UTI SBI incidence is estimated to be negligible
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span>&nbsp;
<br>
|
UA and Ucx alone
OR
treat 57-90d using Philadelphia Protocol
|
Discharge if negative
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient
Admit and tx with CTX if fail criteria for d/c
|-
|
57d-6mo, ≥39 (102.2)
SBI incidence is estimated &lt;1%;
non-UTI SBI incidence is estimated to be negligible.
UTI is 3%–8%
|
UA and Ucx alone
OR
UA and Ucx + CBC + blood cx
|
:
Discharge if negative
Treat for UTI as above
If WBC&gt;15K&nbsp;consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr
If WBC&gt;20K&nbsp;consider CXR and CSF
|-
|
&nbsp;6–36 mo
Non-UTI SBI incidence is &lt;0.4%&nbsp;
UTI in girls ≤8%
UTI in boys (&lt;12 mo) ≤ 2%
Uncircumcised boys (1–2 y) remains 2%
|
UA and Ucx in:
(girls 6-24mo)
(circ 6-12mo)
(uncirc 6-24mo)
|
Discharge if negative
Treat for UTI as above as outpatient
|-
| &gt;36mo
| No further w/u is routinely necessary
| <br>
|}
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d


== See Also  ==
== See Also  ==
Line 375: Line 375:


== Source  ==
== Source  ==
 
*Tintinalli  
Tintinalli  


[[Category:Peds]]
[[Category:Peds]]

Revision as of 04:26, 22 December 2012

From Tintinalli

Management of patients who are well-appearing, vaccinated, and no clinical source of fever

Age Group Evaluation Treatment

0-28d, ≥38C

SBI incidence of ill appearing: 13%–21%

if not ill appearing: <5%

CBC, blood Cx

UA, Ucx

CSF cell count, GS, Cx

CXR (only if resp sx)

Stool testing (if diarrhea present)

Admit

Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg)

29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)


SBI incidence of ill appearing: 13%–21%

if not ill appearing: <5%


Same as for neonates

Discharge if:

1. WBC <15K but >5K and <20% bands

2. UA negative

Admit and perform LP if above are not met

Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis)

57d-6mo, ≥38

Non-UTI SBI incidence is estimated to be negligible

UTI is 3%–8% 


UA and Ucx alone

OR

treat 57-90d using Philadelphia Protocol

Discharge if negative

Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient

Admit and tx with CTX if fail criteria for d/c

57d-6mo, ≥39 (102.2)

SBI incidence is estimated <1%;

non-UTI SBI incidence is estimated to be negligible.

UTI is 3%–8%

UA and Ucx alone

OR

UA and Ucx + CBC + blood cx

Discharge if negative

Treat for UTI as above

If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr

If WBC>20K consider CXR and CSF

 6–36 mo

Non-UTI SBI incidence is <0.4% 

UTI in girls ≤8%

UTI in boys (<12 mo) ≤ 2%

Uncircumcised boys (1–2 y) remains 2%

UA and Ucx in:

(girls 6-24mo)

(circ 6-12mo)

(uncirc 6-24mo)

Discharge if negative

Treat for UTI as above as outpatient

>36mo No further w/u is routinely necessary

Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d

Harbor-UCLA Protocol

Background

  • Medicine is an art as well as science, practice clinical judgment when using this guideline
  • Preemies: Count age by estimated postconception date (not by actual delivery date) for 1st-90d
  • If RSV+ or influenza+
    • Low risk of bacterial illness
    • Still some risk of concurrent UTI

0-28dy

Child Appearance Work Up Treatment Disposition Follow Up
T>=38

Toxic or Well

  1. CBC
  2. Blood Cx
  3. UA, Ucx
  4. LP-CSF
  5. CXR^
  1. Cefotaxime^^ 50-100 mg/kg
  2. Ampicillin 100-200 mg/kg
  3. Acyclovir^^^ 20 mg/kg
Admit N/A
  • ^CXR for (use clinical judgment):
    • Resp symptoms
    • Fever >48 hrs
    • Tachypnea
    • Decreased SaO2
  • ^^Can use ceftriaxone 50-100 mg/kg, but concern for bilirubin displacement
  • ^^^Acyclovir if:
    • HSV infection in baby or mother
    • CSF pleocytoisis
    • Concerning skin lesions
    • Seizures
    • Abnl LFTs

28dy-90dy

Appearance Work Up Treatment Disposition Follow Up
T>=38 + Toxic
  1. CBC
  2. Blood Cx
  3. UA, Ucx
  4. LP-CSF
  5. CXR^
  1. Cefotaxime^^ 50-100 mg/kg
  2. Ampicillin 100 mg/kg
  3. Acyclovir^^^ 20 mg/kg
Admit NA

T>=38 + Well

(Option 1)

  1. CBC
  2. Blood Cx
  3. UA, UCx
  4. LP-CSF
  5. CXR^
  1. Ceftriaxone (50mg/kg IM/IV)

If W/U (+) admit

Outpatient^^^^

If W/U negative, meets outpt

T>=38 + Toxic

(Option 2)

  1. CBC
  2. Blood Cx
  3. UA, UCx
  4. CXR^
  1. None

For very well appearing 60-90 day olds (many would not use this option)

Outpatient^^^^
  • ^CXR for (use clinical judgment):
    • Resp symptoms
    • Fever >48 hrs
    • Tachypnea
    • Decreased SaO2
  • ^^Can use ceftriaxone 50-100 mg/kg, but concern for bilirubin displacement
  • ^^^Acyclovir if:
    • HSV infection in baby or mother
    • CSF pleocytoisis
    • Concerning skin lesions
    • Seizures
    • Abnl LFTs
  • ^^^^Outpatient

90dy-36mo

Appearance Work Up Treatment Disposition Follow Up
T>=39 + Toxic
  1. CBC
  2. Blood Cx
  3. UA, UCx
  4. LP-CSF
  5. CXR^

Ceftriaxone (50-100mg/kg)

OR

Cefotaxime (50-100mg/kg)

AND

Consider Vanco (15mg/kg)^^^^

Admit N/A

T>=39^^^^^ + Well + Prevnar^^

  1. UA, UCx^^^
  2. CXR^

If + W/U, oral abx

Outpatient

T>=39^^^^^ + Well + NO Prevnar^^

  1. UA, UCx^^^
  2. CBC
  3. CXR^

Ceftriaxone 50mg/kg if >15 WBC (also then consider BCx and LP)

Outpatient
T>=38-38.9 + Well

None

Consider UA, CXR based on sx, etc

None

Outpatient Return if worsening sx or fever persists >72hrs
  • ^CXR for (use clinical judgment):
    • Resp symptoms
    • Fever >48 hrs
    • Tachypnea
    • Decreased SaO2
  • ^^Prevnar = has 3 Prevnar or >=4 wks post 2nd Prevnar dose
  • ^^^Urine workup for:
    • Circumcised males <6 months
    • Uncircumcised males <12 months
    • All females
  • ^^^^Vancomycin if evidence of bacterial meningitis on CSF
  • ^^^^^>=39.5 for 24-36mo

Work-Up Results

  • WBC: 5-15, ANC <10k, <1,500 bands
  • UA: (-)Gm Stain, (-) leuks, (-) nitrite, <5-10 wbc/hpf
  • CSF: <8wbc, (-) Gm Stain
  • When diarrhea present, <5 wbc

If low-risk criteria below not met, LP (if not done) and admit for inpt abx

Petechia

  1. CBC
  2. BCx
  3. Ceftriaxone
  4. LP depending on clinical

See Also

Source

  • Tintinalli